Please assess the completion status of the following clinical trial:

Trial Title: Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Fulfilling DSM-IV criteria for Major Depressive Disorder~* Score of Hamilton Rating Scale for Depression (HDRS-17) \> 17~* Patient to be prescribed mirtazapine (Remeron) as determined by physician~* Subject has no known clinically significant abnormal vital signs or other clinical findings at screening.~* Patients should have a driving license for more than 3 years and drive over 15,000 km year.~* Females of childbearing potential must willingly use effective birth control.~Exclusion Criteria:~* Night shift workers.~* A history or present condition of: Bipolar Disorder or Depressive Disorder not Otherwise Specified,Schizophrenia or other psychotic disorders (according to DSM-IV), Schizotypal or Borderline personality disorder, Organic mental disorders~* A present condition of: Anxiety Disorders (according to DSM-IV), Eating Disorders, Postpartum Depression~* Epilepsy or a history of seizure disorder or ever received treatment with anticonvulsant medication for epilepsy or seizures~* PSG recording of an extremely abnormal sleep EEG (other than that which would be expected with depression)~* Alcohol or substance abuse (according to DSM-IV) during the last 6months prior to baseline.~* Any physical disease, which may explain the symptoms of depression.~* Any chronic physical disease, which is not stabilized.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).